|
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov. |
NIDA-CTN-0053
The primary objective of this Phase 3 study is to evaluate the impact of N-Acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50). The primary outcome measure will be the odds of negative weekly urine cannabinoid tests during active treatment. Primary analysis will be based on an intent-to-treat evaluation of all participants randomized into the study, with missing urine specimens coded as missing and assumed to be positive. Sensitivity analyses will be performed to determine how other procedures for missing data affect results.
Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.